Clinical trial NCT02138162: A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
Official title: A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Enzalutamide in Male Subjects With Severe Hepatic Impairment and Normal Hepatic Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Severe Hepatic Impairment
Normal Hepatic Function
Keywords: Phase 1
Pharmacokinetics
Safety
Severe hepatic impairment
Enzalutamide
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Medivation, Inc.
First posted: 2014-05-14
Enrollment: 16
Sex: MALE
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men. The results are compared to the data gained from 8 age- and BMI-matched men with normal liver function.

Detailed description: Screening takes place between Day -22 and Day -2, and subjects are admitted to the clinic on Day -1. Each subject receives a single oral dose of enzalutamide on Day 1, under fasted conditions. They are discharged on Day 7; ambulant visits take place until Day 50. An End of Study Visit (ESV) occurs 7-10 days after the last PK sampling or early withdrawal.

Full PK profiles are obtained for enzalutamide, metabolite 1 of enzalutamide (M1) and metabolite 2 of enzalutamide (M2) up to 1176 hours (Day 50) after administration.

Safety assessments are performed throughout the study. For subjects with severe hepatic impairment, additional Child-Pugh classification and laboratory safety tests (including liver function tests) are performed regularly after administration.

Eligibility criteria: Inclusion Criteria:

* Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
* Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
* Subject has a Body Mass Index (BMI) range of 18.5 - 34.0 kg/m2 inclusive. The subject weighs at least 50 kg \[at Screening\].

Inclusion Criteria:Subjects with severe hepatic impairment must also meet the following inclusion criteria:

* Subject has a Child-Pugh classification Class C (severe, 10 to 15 points).

Inclusion Criteria: For Healthy Subjects Only:

* Age- and BMI-matched to subjects with severe liver hepatic impairment.

Exclusion Criteria:

* Subject has known or suspected hypersensitivity to enzalutamide, or any components of the formulation used.
* Subject has history of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit).
* Subject has used grapefruit (or grapefruit containing products) or marmalade in the week prior to admission to the clinical unit (Day -1), as reported by the subject.

Exclusion Criteria: For Healthy Subjects Only:

* Subject has any of the liver function tests above the upper limit of normal.

Exclusion Criteria: Subjects with severe hepatic impairment must also not have any of the following characteristics:

* Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
* Subject has surgical porto-systemic shunts, including TIPSS (Trans-jugular intrahepatic portosystemic shunt).
* Subject has presence of severe hepatic encephalopathy (grade \> 2).
* Subject has advanced ascites.
* Subject has esophageal variceal bleeding in the medical history (within 6 months before Day -1).
* Subject has thrombocyte level below 40x109 /L and /or hemoglobin below 90 g/L.
* Subject has significant renal dysfunction (creatinine clearance below 50 mL/min, estimated according to the method of Modification of Diet in Renal Disease (MDRD) formula).
* Subject has had previous liver transplantation.

Primary outcomes:
measure: Pharmacokinetics (PK) of enzalutamide after a single oral dose
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
measure: PK of enzalutamide after a single oral dose
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
measure: PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
measure: PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
Secondary outcomes:
measure: PK of enzalutamide, M1, M2 and the sum of enzalutamide plus N-desmethyl enzalutamide (M2)
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
measure: Additional pharmacokinetic variables for enzalutamide, and, as appropriate, for M1 and M2, based upon unbound plasma concentrations
timeFrame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
Other outcomes:
Locations:
city: Sofia
country: Bulgaria
facility: Comac Medical Ltd.
Study officials:
affiliation: Astellas Pharma Europe B.V.
name: Medical Monitor
role: STUDY_DIRECTOR
References: